Efecto de los ácidos grasos poliinsaturados omega-3 sobre la función cognitiva en pacientes con deterioro cognitivo leve / No disponible

Introducción: el deterioro cognitivo leve (DCL) afecta a entre el 3 y el 17 % de la población anciana, con tasas de conversión a demencia del 10 % al año. Distintos estudios publicados han mostrado el beneficio de los ácidos grasos poliinsaturados omega-3 (omega-3) en pacientes con DCL. Objetivo: evaluar el efecto de un complemento alimenticio a base de ácidos grasos omega-3 (ácido docosahexaenoico [DHA] y ácido eicosapentaenoico [EPA]) sobre el estado cognitivo y anímico en mayores de 60 años con DCL. Materiales y métodos: se seleccionaron 60 pacientes mayores de 60 años con DCL que fueron divididos aleatoriamente en dos grupos: grupo con complemento de omega-3 (grupo omega-3) y grupo control. Se efectuó una visita basal y otra a las 24 semanas. En cada visita se realizó: test de mini-mental (MMSE por sus siglas en inglés), test de Barcelona abreviado (TB-A) y escala de calidad de vida EQ-5D. Se analizaron las diferencias obtenidas entre las dos visitas y entre ambos grupos. Resultados: 46 (76,7 %) pacientes completaron el estudio: 25 del grupo omega-3 y 21 del grupo control. No encontramos diferencias entre ambos grupos en la puntuación del MMSE. Se halló mejoría significativa (p = 0,025) a favor del grupo omega-3 en el ítem «Memoria de textos diferida (preguntas)» del TB-A y mejoría significativa en el apartado ansiedad/depresión del EQ-5D a favor del grupo omega-3 (p = 0,005). El complemento de omega-3 fue bien tolerado. Conclusión: tras 24 semanas de seguimiento, el complemento de omega-3 ha mostrado un efecto positivo en la memoria y en el estado anímico. Estos resultados son equiparables a los publicados anteriormente, aunque se trata del primer estudio de estas características realizado en España (AU)

Introduction: Mild cognitive impairment (MCI) affects between 3-17% of the elderly, with conversion rates to dementia of 10% per year. Different published studies have shown the benefit of omega-3 polyunsaturated fatty acids (omega-3) in patients with MCI. Objective: To assess the effect of an omega-3 polyunsaturated fatty acids (docosahexaenoic acid [DHA] and eicosapentaenoic acid [EPA]) food supplement on cognitive state and mood in people aged 60 years and above with MCI. Methods: 60 patients aged 60 years and above with MCI were recruited and were randomly divided into two groups: group with an omega-3 supplement (omega-3 group) and control group. A basal visit and a visit after 24 weeks were conducted. A minimental state examination (MMSE), an abbreviated Barcelona test (a-BT) and a EQ-5D quality of life scale were made in every visit. The differences between both visits and both groups were analyzed. Results: 46 patients completed the study (76.7%), 25 from the omega-3 group and 21 from the control group. There were no differences between both groups for the MMSE score. A significant improvement (p = 0.025) in favour of the omega-3 group for the "Deferred text memory (questions)" item in the a-BT and a significant improvement (p = 0.005) in favour of the omega-3 group for the anxiety/depression section in the EQ-5D were found. Omega-3 supplement was well tolerated. Conclusion: After 24 weeks of follow-up, the omega-3 supplement has shown a benefit on memory and mood. These results are comparable to those published earlier, although this is the first time that such a study has been conducted in Spain (AU)

Age-specific thyroid hormone and thyrotropin reference intervals for a pediatric and adolescent population.

BACKGROUND: Establishment of reliable reference intervals remains valuable for confirming validity and advancing standardization across methods and populations. Moreover, knowledge of the measurement uncertainty (U) and of the reference change value (RCV) has important applications in clinical chemistry. METHODS: Starting from the information available in the laboratory data base (29,901 subjects) an initial selection was carried out by eliminating all subjects with a clinical or laboratory pathological report; data from 7581 0- to 20-year-old subjects (53.87% girls) remained in the study. These subjects, divided into nine age groups, were used to define reference distribution percentiles (2.5th, 50th and 97.5th) of serum thyrotropin (TSH), triiodothyronine (T3), thyroxine (T4), and free T4 (fT4), as well as U and RCV of these assays. RESULTS: In early infancy, T4 and fT4 values were higher than in the older age groups. Serum T4 95th percentile reference value, useful for the diagnosis of hyperthyroidism, was 142.9 in 20-year-old boys and 230.4 nmol/L in early infants and serum T3 95th percentile was 2.6 and 3.5 nmol/L, respectively, while fT4 2.5th percentile reference value, useful for the diagnosis of hypothyroidism, was 9.6 and 13.0 pmol/L, respectively. Serum TSH 97.5th percentile showed less age variation, 4.38-4.88 mIU/L. Performance of the four assays resulted in approximately 20% Us, reflecting simple and complex imprecision, trueness, analytical and functional sensitivity. RCV of serum TSH (58.6%) was larger than for thyroid hormones (28.3%-34.7%), probably due to the high biological variation of this hormone. CONCLUSIONS: We have established reference interval for TSH and thyroid hormones, as well as Us for assessing reliability of measurements, and RCVs to alert users on the presence of clinical significant changes.